EP
UTHR icon

Eversept Partners’s United Therapeutics UTHR Stock Holding History

Eversept Partners’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-7,600
Closed -$1.64M – 106
2021
Q4 		$1.64M Buy
+7,600
New +$1.49M 0.1% 83

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Eversept Partners's UTHR Position: Q1 2026 in Review

Eversept Partners increased its United Therapeutics (UTHR) stake by 4.6% in Q1 2026, buying an estimated $5.82M and bringing the position to 264,271 shares worth $157M. The position accounts for 8.26% of the portfolio, ranked #1.

Eversept Partners first reported a position in UTHR in Q2 2020 and has held it in 24 quarters since. 850 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

  • Eversept Partners held 264,271 shares of United Therapeutics worth $157M as of Q1 2026.
  • Eversept Partners bought 11,679 United Therapeutics shares in Q1 2026, an estimated $5.82M.
  • United Therapeutics made up 8.26% of Eversept Partners's portfolio in Q1 2026, its #1 holding.
  • Eversept Partners first reported a position in United Therapeutics in Q2 2020 and has held it in 24 quarters since.
  • 850 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on Eversept Partners's 13F filing for Q1 2026, filed 15 May 2026.